Room1810, Future Time Zhongshan Road
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.
Advantage Description：
This is Daisy from Hebei Lingding Biotechnology in China.
We specialized in pharmaceutical intermediates for 10 years,high quality and competitive price, and hope to find a way to cooperate with you!
We are mainly suppliers of pharmaceutical intermediates,peptides, steroids, SARMS, Estrogen, etc.
Whatsapp:+86 19933155940
Email:hbldbiotech@gmail.com
Wickr: daisyhou
Company Profile：
The company’s products are sold all over the world, mainly exported to the United States, Europe, Southeast Asia, Australia, the Middle East and South Africa and other countries. The company has a strong scientific research and technical team, can provide customers with high quality products and a full range ofservices. We will provide firstclass products and better service to face the needs of customers, to meet the challenges of the market. Welcome domestic and foreign customers to negotiate.
Our Advantages：
1.Any inquiry or message will be replied within 12 hours.
2.Professional manufacturer. Welcome to visit our website.
3.API, Intermediate are available, we can offer Custom Synthesis, and registration as well.
4.Fast delivery.
5.After-sale services
Контактна особа: Daisy Hou
